Arcutis Biotherapeutics Inc (NASDAQ: ARQT) — Company Overview, News & Financial Data
Arcutis Biotherapeutics develops innovative dermatological treatments aimed at improving the lives of patients with skin conditions.
Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics (NASDAQ:ARQT) is a biopharmaceutical company focused on developing innovative treatments for patients dealing with dermatological diseases. The company has dedicated its research and development efforts to creating highly differentiated therapies to improve the lives of those burdened by skin conditions. Its portfolio boasts projects aimed at tackling prevalent issues such as psoriasis, atopic dermatitis, and other skin diseases with significant unmet needs. Arcutis's objectives center around leveraging its expertise in dermatology to bring forward new, effective treatments that can offer both safety and efficacy, providing relief and improved quality of life for patients. With a deep commitment to science and patient care, Arcutis Biotherapeutics aims to leave a lasting impact on the field of dermatology by addressing and fulfilling the needs of a diverse patient population.
Snapshot
Operations
Products and/or services of Arcutis Biotherapeutics Inc
- Roflumilast cream, designed for chronic plaque psoriasis treatment, harnessing anti-inflammatory properties.
- Roflumilast foam aimed at treating seborrheic dermatitis and scalp psoriasis, focusing on inflammation reduction.
- Topical formulation developments for vitiligo, enhancing repigmentation strategies.
- Innovative therapies targeting atopic dermatitis, emphasizing symptom relief and skin barrier restoration.
- Research on JAK inhibitors for dermatological conditions, exploring novel anti-inflammatory pathways.
- Pipeline expansion in alopecia areata, investigating treatments to stimulate hair regrowth.
Arcutis Biotherapeutics Inc executive team
- Todd Franklin WatanabePresident, CEO & Director
- Bhaskar ChaudhuriCo-Founder & Director Emeritus
- Latha VairavanSenior VP & Chief Financial Officer
- Masaru MatsudaExecutive VP, Chief Legal Officer & Corporate Secretary
- Patrick E. BurnettExecutive VP & Chief Medical Officer
- Brian SchoelkopfHead of Investor Relations
- Steve AriasVice President of Compliance & Privacy
- Amanda SheldonHead of Corporate Communications
- Aleen HosdaghianVice President of Marketing
- Todd TuckerSenior VP & Chief Human Resources Officer
Latest news about Arcutis Biotherapeutics Inc
Key financials
Reported results for Arcutis Biotherapeutics Inc, in USD.
- Market cap
- 4B
- Revenue (TTM)
- 464M
- P/E ratio
- 145.3
- EPS (diluted, TTM)
- 0.2
- Dividend yield
- —
- Profit margin
- 6.2%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 376.1M | -12.2M | -16.1M | |
| 196.5M | -128.4M | -140M | |
| 59.6M | -241.1M | -262.1M | |
| 3.7M | -301.6M | -311.5M |